NASDAQ:TELA TELA Bio (TELA) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free TELA Stock Alerts $5.67 +0.06 (+1.07%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$5.57▼$5.7850-Day Range$5.30▼$7.6152-Week Range$4.23▼$11.65Volume82,453 shsAverage Volume122,655 shsMarket Capitalization$139.77 millionP/E RatioN/ADividend YieldN/APrice Target$13.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get TELA Bio alerts: Email Address TELA Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside141.0% Upside$13.67 Price TargetShort InterestBearish2.92% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.61) to ($1.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.96 out of 5 starsMedical Sector587th out of 938 stocksSurgical & Medical Instruments Industry62nd out of 94 stocks 3.5 Analyst's Opinion Consensus RatingTELA Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.67, TELA Bio has a forecasted upside of 141.0% from its current price of $5.67.Amount of Analyst CoverageTELA Bio has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.92% of the outstanding shares of TELA Bio have been sold short.Short Interest Ratio / Days to CoverTELA Bio has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in TELA Bio has recently increased by 8.62%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTELA Bio does not currently pay a dividend.Dividend GrowthTELA Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TELA. Previous Next 2.4 News and Social Media Coverage News SentimentTELA Bio has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for TELA Bio this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for TELA on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows1 people have added TELA Bio to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TELA Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.70% of the stock of TELA Bio is held by insiders.Percentage Held by Institutions94.35% of the stock of TELA Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TELA Bio are expected to grow in the coming year, from ($1.61) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TELA Bio is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TELA Bio is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTELA Bio has a P/B Ratio of 7.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About TELA Bio Stock (NASDAQ:TELA)TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.Read More TELA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TELA Stock News HeadlinesMarch 25, 2024 | msn.comTELA Bio Stands Tall With Consistent Growth, Novel Products, and a Promising Revenue Projection for 2024March 24, 2024 | finance.yahoo.comAnalysts Are Updating Their TELA Bio, Inc. (NASDAQ:TELA) Estimates After Its Full-Year ResultsMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 24, 2024 | americanbankingnews.comTELA Bio (NASDAQ:TELA) Rating Reiterated by JMP SecuritiesMarch 24, 2024 | americanbankingnews.comPiper Sandler Lowers TELA Bio (NASDAQ:TELA) Price Target to $12.00March 23, 2024 | seekingalpha.comTELA Bio, Inc. (TELA) Q4 2023 Earnings Call TranscriptMarch 23, 2024 | finance.yahoo.comTELA Bio Full Year 2023 Earnings: US$2.04 loss per share (vs US$2.72 loss in FY 2022)March 22, 2024 | stockhouse.comTELA Bio Announces U.S. Commercial Launch of LIQUIFIX(TM) - the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia SurgeryMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 22, 2024 | finance.yahoo.comTELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | finance.yahoo.comQ4 2023 TELA Bio Inc Earnings CallMarch 21, 2024 | benzinga.comRecap: TELA Bio Q4 EarningsMarch 21, 2024 | msn.comTELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q4 2023March 21, 2024 | finance.yahoo.comTELA Bio Inc Reports Robust Revenue Growth in Q4 and Full Year 2023March 21, 2024 | markets.businessinsider.comStrategic Divestiture and Innovative Product Launch Fuel Buy Rating for TELA BioMarch 21, 2024 | finance.yahoo.comTELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial ResultsMarch 21, 2024 | globenewswire.comTELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial ResultsMarch 21, 2024 | markets.businessinsider.comTela Bio Announces Commercial Launch Of Liquifix Devices In U.S.March 21, 2024 | globenewswire.comTELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia SurgeryMarch 20, 2024 | marketwatch.comTELA Bio Sells Distribution Rights to Wound-Care Product to MimedxMarch 20, 2024 | markets.businessinsider.comTELA Bio is about to announce its earnings — here's what to expectMarch 20, 2024 | globenewswire.comTELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDXMarch 7, 2024 | finance.yahoo.comTELA Jul 2024 10.000 callMarch 7, 2024 | finance.yahoo.comTELA Jul 2024 7.500 putFebruary 29, 2024 | globenewswire.comTELA Bio to Announce Fourth Quarter and Full Year 2023 Financial ResultsFebruary 25, 2024 | msn.comTELA Bio Awards Restricted Stock Units to New Hires in Bid to Attract Top TalentFebruary 23, 2024 | globenewswire.comTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive TELA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TELA Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:TELA CUSIPN/A CIK1561921 Webwww.telabio.com Phone484-320-2930FaxN/AEmployees173Year FoundedN/APrice Target and Rating Average Stock Price Target$13.67 High Stock Price Target$15.00 Low Stock Price Target$12.00 Potential Upside/Downside+141.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,660,000.00 Net Margins-79.83% Pretax Margin-79.83% Return on Equity-201.62% Return on Assets-58.60% Debt Debt-to-Equity Ratio2.15 Current Ratio4.23 Quick Ratio4.43 Sales & Book Value Annual Sales$58.45 million Price / Sales2.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.75 per share Price / Book7.56Miscellaneous Outstanding Shares24,650,000Free Float23,245,000Market Cap$139.77 million OptionableOptionable Beta0.97 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Antony Koblish (Age 58)Co-founder, President, CEO & Director Comp: $967.67kMr. Roberto E. Cuca J.D. (Age 56)CFO & COO Comp: $643.37kMr. Paul TalmoChief Technology OfficerMs. Megan Smeykal (Age 48)VP, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer Mr. D. Taylor OcasioGeneral Counsel & Corporate SecretaryMs. Jennifer Lou Armstrong (Age 54)Senior Vice President of Human Resources Mr. Gregory A. FirestoneChief Business OfficerMr. Michael LeonardSenior Vice President of Technical OperationsMr. Peter C. Murphy (Age 51)Chief Commercial Officer Comp: $542.34kLouisa SmithInvestor Relations Contact OfficerMore ExecutivesKey CompetitorsNeuroneticsNASDAQ:STIMHealth Sciences Acquisitions Co. 2NASDAQ:HSAQDelcath SystemsNASDAQ:DCTHKORU Medical SystemsNASDAQ:KRMDClearPoint NeuroNASDAQ:CLPTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 22,850 shares on 3/11/2024Ownership: 4.079%Spouting Rock Asset Management LLCSold 2,602 shares on 2/16/2024Ownership: 0.077%Nuveen Asset Management LLCBought 8,220 shares on 2/15/2024Ownership: 0.126%Barclays PLCBought 19,341 shares on 2/15/2024Ownership: 0.091%Citadel Advisors LLCSold 200 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions TELA Stock Analysis - Frequently Asked Questions Should I buy or sell TELA Bio stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TELA Bio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TELA shares. View TELA analyst ratings or view top-rated stocks. What is TELA Bio's stock price target for 2024? 3 Wall Street analysts have issued 1-year target prices for TELA Bio's stock. Their TELA share price targets range from $12.00 to $15.00. On average, they anticipate the company's stock price to reach $13.67 in the next year. This suggests a possible upside of 141.0% from the stock's current price. View analysts price targets for TELA or view top-rated stocks among Wall Street analysts. How have TELA shares performed in 2024? TELA Bio's stock was trading at $6.62 on January 1st, 2024. Since then, TELA shares have decreased by 14.4% and is now trading at $5.67. View the best growth stocks for 2024 here. When is TELA Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our TELA earnings forecast. How were TELA Bio's earnings last quarter? TELA Bio, Inc. (NASDAQ:TELA) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.05. The company earned $7.65 million during the quarter, compared to the consensus estimate of $7.30 million. TELA Bio had a negative trailing twelve-month return on equity of 201.62% and a negative net margin of 79.83%. What guidance has TELA Bio issued on next quarter's earnings? TELA Bio issued an update on its FY 2024 earnings guidance on Thursday, March, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $74.0 million-$76.0 million, compared to the consensus revenue estimate of $75.2 million. What other stocks do shareholders of TELA Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other TELA Bio investors own include Micron Technology (MU), Intel (INTC), Pfizer (PFE), CrowdStrike (CRWD), Walt Disney (DIS), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Alteryx (AYX) and Cisco Systems (CSCO). When did TELA Bio IPO? TELA Bio (TELA) raised $60 million in an initial public offering (IPO) on Friday, November 8th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers. Who are TELA Bio's major shareholders? TELA Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include First Light Asset Management LLC (10.43%), AIGH Capital Management LLC (5.63%), Nantahala Capital Management LLC (4.48%), Vanguard Group Inc. (4.08%), Vanguard Group Inc. (4.08%) and UBS Group AG (2.81%). Insiders that own company stock include Antony Koblish, Ew Healthcare Partners Fund 2-, Ew Healthcare Partners Fund 2,, Gregory A Firestone, Opaleye Management Inc, Orbimed Advisors Llc and Roberto Cuca. View institutional ownership trends. How do I buy shares of TELA Bio? Shares of TELA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TELA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TELA Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.